When will adaptogen drinks cross from niche to mainstream in Europe?
Adaptogen drinks — beverages containing herbs and fungi traditionally classified as “adaptogens” (substances that help the body adapt to stress) — are positioned at the intersection of the premium NA drinks trend and the functional wellness market. Ashwagandha, reishi, lion's mane, rhodiola, eleuthero, and schisandra are the most commercially visible adaptogens in NA drink formulations as of 2026. The category crossed into mainstream US retail in 2024–2025 (Erewhon, Whole Foods, Sprouts stocking dozens of adaptogen NA SKUs), but European mainstream adoption remains 18–36 months behind, primarily due to EU Novel Food regulation barriers that restrict the use of several key adaptogenic ingredients.
The primary obstacle to European mainstream adaptogen drink adoption is regulatory rather than consumer demand. The EU Novel Food Regulation (2015/2283) requires novel food ingredients — which includes many adaptogenic herbs that were not widely consumed in the EU before 1997 — to undergo a safety assessment before they can be marketed in conventional food products. Ashwagandha (Withania somnifera) is classified as Novel Food in the EU, meaning products containing it require Novel Food authorisation before sale. Lion's mane (Hericium erinaceus) occupies a grey zone — traditional in Asia but legally ambiguous in the EU. Reishi (Ganoderma lucidum) has more established EU precedent as a food supplement ingredient.
These regulatory constraints have produced a bifurcated European market: food supplements (sold in pharmacies and health food stores, clearly labelled and dosed) can contain most adaptogens; conventional beverages marketed to the general public face much higher barriers. This means European adaptogen drinks are currently predominantly positioned as “health drinks” or “wellness supplements in liquid form” rather than as mainstream refreshment beverages — a positioning that limits volume but supports premium pricing.
The path to European mainstream is more likely to go through proven Novel Food authorisations for key adaptogens (ashwagandha applications are in EU process) and through the natural regulatory lag that follows US market success. When major US beverage companies achieve large-scale adaptogen drink sales, they typically engage EU regulatory processes, and their volume justifies the multi-year authorisation investment that smaller producers cannot afford.
Surprising fact: Functional mushroom drinks (lion's mane, reishi, chaga) are growing at 89% year-on-year in the US specialist retail channel as of 2025, making them the fastest-growing single ingredient category in NA beverages — but the same products are largely unavailable in conventional European food retail due to Novel Food status, creating a two-speed global market that has no historical precedent in the beverages industry.
| Adaptogen | EU Regulatory Status | EU Market Access | Mainstream Timeline |
|---|---|---|---|
| Ashwagandha | Novel Food (in process) | Supplement only | 2026–2027 if authorised |
| Lion's Mane | Grey zone / Novel Food | Supplement, limited beverage | 2027–2028 |
| Reishi | More established precedent | Supplement + some beverages | 2025–2026 |
| Rhodiola | Supplement status established | Supplement | Slower (less consumer pull) |
| Schisandra | Varies by country | Mixed across EU | Uncertain |
zeroproof.one monitors European adaptogen drink regulation and consumer adoption — your guide to what's actually available now and what's coming in the European NA functional drinks market.